Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy?
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Szczapa-Jagustyn, J. An update on thyroid-associated ophthalmopathy in children and adolescents. J. Pediatr. Endocrinol. Metab. 2016, 29, 1115–1122. [Google Scholar] [CrossRef] [PubMed]
- Krassas, G.E. Childhood Graves’ ophthalmopathy: Results of a European questionnaire study. Eur. J. Endocrinol. 2005, 153, 515–521. [Google Scholar] [CrossRef] [PubMed]
- Gogakos, A.I. Pediatric aspects in Graves’ orbitopathy. Pediatr. Endocrinol. Rev. 2010, 7 (Suppl. 2), 234–244. [Google Scholar] [PubMed]
- Flynn, J.T.; Kaelber, D.C.; Baker-Smith, C.M. Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017, 140, e20171904. [Google Scholar] [CrossRef] [PubMed]
- Cacciari, E. Cross sectional growth charts for height weight and BMI (2 ToYr). J. Endocrinol. Investig. 2006, 29, 581–593. [Google Scholar] [CrossRef] [PubMed]
- Bartalena, L. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 2008, 158, 273–285. [Google Scholar] [CrossRef] [PubMed]
- Marcocci, C. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26, 325–337. [Google Scholar] [CrossRef] [PubMed]
- Krassas, G. Thyoid-associated ophthalmopathy in juvenile Graves’ disease: Clinical, endocrine and therapeutic aspects; thyroid in childhood and adolescence. J. Pediatr. Endocrinol. Metab. 2006, 19, 1193–1206. [Google Scholar] [CrossRef] [PubMed]
- Wiersinga, W.M. Clinical assessment of patients with Graves’ orbitopathy: The European Group on Graves’ orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol. 2006, 155, 387–389. [Google Scholar] [PubMed]
- Mourits, M.P. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. 1997, 47, 632. [Google Scholar] [CrossRef]
- Dickinson, A.J. Clinical manifestations. In Graves’ Orbitopathy. A Multidisciplinary Approach-Questions and Answers, 2nd, Revised Version; Wiersinga, W.M., Ed.; Karger: Basel, Switzerland, 2010; pp. 1–25. [Google Scholar]
- Kaleva, N.N. Contemporary diagnostic and therapeutic abilities in childhood thyroid-associated ophthalmopathy with a clinical case description. Folia Medica 2010, 52, 57–63. [Google Scholar] [CrossRef] [PubMed]
- Kahaly, G.J. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 2005, 90, 5234–5240. [Google Scholar] [CrossRef] [PubMed]
- Marcocci, C. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: Results of a prospective, single-blind, randomized study. J. Clin. Endocrinol. Metab. 2001, 86, 3562–3567. [Google Scholar] [PubMed]
- Hart, R.H. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J. Ocul. Pharmacol. Ther. 2005, 21, 328–336. [Google Scholar] [CrossRef] [PubMed]
- Krassas, G.E. Corticosteroids in the medical treatment of thyroid ophtalmopathy: When and how? Somatostatin analogues: Where we stand today. Pediatr. Endocrinol. Rev. 2010, 7 (Suppl. 2), 204–209. [Google Scholar] [PubMed]
- Le Moli, R. Determinants of liver damage associated with intravenous methylprednisolone pulse theraphy in Graves’ ophtalmopathy. Thyroid 2007, 17, 357–362. [Google Scholar] [CrossRef] [PubMed]
- Hart, R.H. Glucocorticoids in the medical management of Graves’ ophthalmopathy. Minerva Endocrinol. 2003, 28, 223–231. [Google Scholar] [PubMed]
- Rivkees, S.A. The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J. Clin. Endocrinol. Metab. 1998, 83, 3767–3776. [Google Scholar] [PubMed]
Parameter | Timeline | ||||||||
---|---|---|---|---|---|---|---|---|---|
Admission | 1 m | 2 m | 3 m | 4 m | 5 m | 6 m | 8 m | 12 m | |
Graves’ ophthalmopathy | Mild EP and conjunctival hyperemia | Worsening EP, palpebral retraction, soft tissue involvement, keratopathy and conjunctival hyperemia | Reduced EP | Reduced EP, moderate conjunctival hyperemia | No EP | ||||
TSH (µUI/mL) (n.v. 0.27–4.2) | 0.0001 | 0.005 | 0.005 | 0.005 | 0.007 | 0.127 | 0.182 | 1.11 | 1.730 |
FT3 (pg/mL) (n.v. 2–4.4) | 4.10 | 7.32 | 6.51 | 5.62 | 3.53 | 2.450 | 3.59 | 4.26 | 4.28 |
FT4 (ng/dL) (n.v. 0.9–1.7) | 2.75 | 1.65 | 1.64 | 1.58 | 1.17 | 0.97 | 1.49 | 1.3 | 1.30 |
Hearth rate (bpm) | 140 | 88 | 80 | 74 | |||||
Blood pressure (mmHg) | 100/65 | 108/67 | 98/65 | 103/58 | 101/75 | ||||
Therapy with methimazole (mg/kg/die) | 0.4 | 0.4 | 0.27 | 0.27 | 0.27 | 0.18 | 0.08 | 0.08 | 0.17 |
Therapy with prednisone | 1 mg/kg/die | 0.45 mg/kg/die | Stopped |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Penta, L.; Muzi, G.; Cofini, M.; Leonardi, A.; Lanciotti, L.; Esposito, S. Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy? Int. J. Environ. Res. Public Health 2019, 16, 155. https://doi.org/10.3390/ijerph16010155
Penta L, Muzi G, Cofini M, Leonardi A, Lanciotti L, Esposito S. Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy? International Journal of Environmental Research and Public Health. 2019; 16(1):155. https://doi.org/10.3390/ijerph16010155
Chicago/Turabian StylePenta, Laura, Giulia Muzi, Marta Cofini, Alberto Leonardi, Lucia Lanciotti, and Susanna Esposito. 2019. "Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy?" International Journal of Environmental Research and Public Health 16, no. 1: 155. https://doi.org/10.3390/ijerph16010155